Participants 495 625 4
OBJECTIVE To assess disease response and to compare the response rates of patients treated with PUVA alone or PUVA and bexarotene.
Participants 626 821 4
METHODS EORTC 21011 (NCT 00056056) was a randomized phase III study comparing combined bexarotene (Targretin(Â®) ) and PUVA vs. PUVA alone in patients with stage IB and IIA mycosis fungoides (MF)
Participants 1053 1156 5
 Of the 93 randomized patients, 87 started treatment, 41 received PUVA and 46 received PUVA + bexaroten
